ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMSpese di vendita, generali e amministrative1.61 B1.6 B1.72 B1.74 B1.83 B1.78 B7.07 BRicerca e sviluppo459 M443 M526 M514 M569 M516 M2.13 BReddito operativo675 M921 M819 M1.05 B825 M1.1 B3.79 BProventi non operativi, Totale-115 M-144 M341 M-120 M-173 M219 M267 MOneri finanziari, al netto degli interessi capitalizzati80 M82 M90 M87 M90 M90 M357 MProventi non operativi, esclusi gli oneri finanziari-106 M-110 M129 M-97 M-139 M68 M-39 MEntrate/uscite straordinarie-89 M-116 M122 M-110 M-124 M61 M-51 MUtile al lordo delle imposte585 M805 M941 M939 M700 M1.16 B3.74 BQuota di utile———————Imposte23 M133 M146 M183 M31 M-176 M184 MInteressi di minoranza-5 M-2 M-2 M0-2 M-2 M-6 MAltri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate563 M672 M795 M755 M670 M1.34 B3.56 BAttività cessate———————Utile netto563 M672 M795 M755 M670 M1.34 B3.56 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari565 M674 M797 M755 M672 M1.34 B3.56 BUtile base per azione (EPS base)0.380.460.540.510.450.92.4Utile diluito per azione (EPS diluito)0.380.450.530.510.450.92.39Numero medio di azioni ordinarie in circolazione1.47 B1.48 B1.48 B1.48 B1.48 B1.48 B—Azioni diluite in circolazione1.49 B1.49 B1.49 B1.5 B1.49 B1.5 B—EBITDA1.02 B1.25 B1.16 B1.39 B1.19 B1.45 B5.18 BEBIT676 M922 M819 M1.05 B823 M1.1 B3.79 BCosto del fatturato1.47 B1.45 B1.64 B1.52 B1.61 B1.59 B6.36 BAltri costi del venduto———————Ammortamento e svalutazione (liquidità)348 M325 M336 M342 M365 M351 M1.39 B
Boston Scientific Corporation Common Stock
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.